Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer
about
Interleukin-15 biology and its therapeutic implications in cancerCytokine-Induced Modulation of Colorectal CancerHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyThe shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyCytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma modelCharacterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.IL-15 deficient tax mice reveal a role for IL-1α in tumor immunitySystemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity.Metabolomics coupled with proteomics advancing drug discovery toward more agile development of targeted combination therapies.Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity.Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myelomaVaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.Unravelling the complexity of cancer-immune system interplay.Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?Stimulating natural killer cells to protect against cancer: recent developments.The use of agonistic anti-CD40 therapy in treatments for cancer.Immunotherapeutic applications of IL-15.The role of KIR genes and ligands in leukemia surveillance.Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.Interleukin-15 in the treatment of cancer.Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.Emerging cytokine networks in colorectal cancer.Novel targets for natural killer/T-cell lymphoma immunotherapy.IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.Checkpoint inhibition for colorectal cancer: progress and possibilities.Interleukin 15 receptor alpha rs2228059 A > C polymorphism decreased risk of gastric cardiac adenocarcinoma in a Chinese population.IL15 combined with Caspy2 provides enhanced therapeutic efficiency against murine malignant neoplasm growth and metastasis.Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells.Angiostatic properties of sulindac and celecoxib in the experimentally induced inflammatory colorectal cancer.The potential and promise of IL-15 in immuno-oncogenic therapies.Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis.IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.Distinct human circulating NKp30FcεRIγCD8 T cell population exhibiting high natural killer-like antitumor potential
P2860
Q24595605-9AC9BC88-8BF6-4F85-B7B3-9B00DBE41210Q26752374-685EE5A3-4F2C-458D-808B-8AFDFA66D425Q27021570-5B9FC659-C2ED-4530-B100-62AAB6B0420CQ28088784-DE97BC91-F854-4131-BC5D-DA73EFE01EA9Q33680566-103FFD87-B661-485C-98C1-891526EED99CQ34420239-800ABC87-4BDF-4DC8-A17B-A5DB60E90F74Q34708192-71D6A061-E9DF-4391-A163-5873B8E0FA14Q34936507-62D874BD-635E-4021-A0E1-1FFFE1363D6DQ35001598-7BD035E3-E90F-478A-9B60-B087933AE0B9Q35085001-D14716DC-1CD3-441A-8616-55DA5BB3AE7CQ35572171-9D0C59B1-896D-47CC-BAED-6398DA078012Q35979037-C0F1F800-FF68-43FD-B477-BFAA6F0F8BF0Q36016696-9413BFF0-586D-4820-9EE1-D081C064C963Q36060253-44CF8922-F479-4C74-87E4-D0EAC2A55583Q36832472-A9A8D343-832F-4B56-879F-48829761B22CQ36923835-9229D1E1-0EE0-4ED9-9194-638EB5F39E8DQ37412903-56D8089B-AF5F-4523-815A-CD78BFCDC680Q37557639-FA5BBF6A-720B-4716-85E9-F9BA68E4E272Q37685855-C68DE4E8-9A2F-48A3-8B12-F16D679B1001Q37765590-ED4597CB-041A-49EC-8E13-9FDE557F8564Q37773303-DA8A0BD9-5C81-4807-A2CC-40BFFCB09D50Q37877269-080CDC98-6412-487E-AA49-9587FB8D8A8FQ38026924-4EA02DAE-6419-4262-A2C7-1474B314C07CQ38050510-D2AF817A-FD8A-4A66-BEED-7A27516B8D7EQ38081103-246200C7-783C-424E-A601-898E98927DBEQ38099680-6A3DB9B6-03AB-4FA1-8383-1FB82DBE27C5Q38264072-A250E00B-EB5D-4BE1-83C3-32D900914A8BQ38544057-88F7D70C-1D56-47DC-8EA4-54C6D6FA3988Q38584430-64E0B5BE-DFE9-4703-9F12-EDE90249A812Q38661106-F536B282-3169-4549-B22C-3F8619E9A2FFQ38768952-433BD1D6-25EE-4CF5-812A-109D58F16F18Q38838641-4C6F09BE-23E0-48A6-888E-68FB4118CD6BQ39217043-78ABE564-E133-4018-898E-853EAF917AEAQ39357728-EC2AC32F-7ADE-42C0-A6ED-0C3332E41BC6Q39666493-ECC54FA9-42A2-4F75-A5D0-AF4DA17C6024Q43601028-2E4E5BEE-947A-4B0B-A469-A5F6B54C0272Q49216382-8AEC0B91-D570-4888-8AA8-43BB0B9BEE55Q51647817-F7BDE0D3-B960-4EA8-ADDB-69122E999526Q54530047-E0C448AF-2BBA-4115-9BBD-918E4C27D879Q57270695-2C188CDE-956C-4DF0-9B1E-5A9855BECA50
P2860
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interleukin-15 combined with a ...... murine models of colon cancer
@en
Interleukin-15 combined with a ...... murine models of colon cancer.
@nl
type
label
Interleukin-15 combined with a ...... murine models of colon cancer
@en
Interleukin-15 combined with a ...... murine models of colon cancer.
@nl
prefLabel
Interleukin-15 combined with a ...... murine models of colon cancer
@en
Interleukin-15 combined with a ...... murine models of colon cancer.
@nl
P2093
P2860
P356
P1476
Interleukin-15 combined with a ...... murine models of colon cancer
@en
P2093
Jürgen R Müller
Meili Zhang
Sigrid Dubois
Thomas A Waldmann
Zhengsheng Yao
P2860
P304
P356
10.1073/PNAS.0902637106
P407
P577
2009-04-21T00:00:00Z